Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Sometimes you win, sometimes you learn.
Glad for the opportunity of presenting the first prospective data of SG (+trastuzumab) after T-DXd in HER2+ MBC, suggesting limited activity despite target switch.
Grateful for mentorship by Ada Waks during the conduction of the trial.”
Other Articles Featuring Paolo Tarantino On OncoDaily.